On-going studies evaluating first-line therapies for metastatic urothelial cancer

TherapyNumberPhasePrimary EndpointTrial IDEstimated Completion Date
Atezolizumab + Gemcitabine/Carboplatin vs. Gemcitabine/Carboplatin (IMvigor 130)1200IIIPFS/OSNCT02807636July 2020
Pembrolizumab +/− Platinum vs Gemcitabine/Platinum (Keynote 361)990IIIPFS/OSNCT02853305March 2020
Durvalumab +/− Tremelimumab vs. Gemcitabine/Carboplatin (1:1:1)525IIIPFS/OSNCT02516241July 2019
Pembrolizumab + CVA21 (Coxsackievirus A21)90ISafetyNCT02043665August 2019
Nivolumab + NEO-PV-1 (personalized peptide vaccine)90IbSafetyNCT02897765December 2020
Pembrolizumab + sEphB4-HSA60IIOSNCT02717156November 2020
Gemcitabine/Cisplatin +/− Ipilimumab (Active, not accruing)36IISafety/ORRNCT01524991November 2017
Atezolizumab +/− Gemcitabine Cisplatin (First line metastatic or MIBC)30I/IISafetyNCT02989584December 2020